Bottom line. Physician investors should treat the FTC Health Breach Notification Rule as an operating and valuation issue for consumer health apps, not as a narrow post-hacking requirement. The amended rule, effective July 29, 2024, clarifies that many non-HIPAA health apps can be covered and that an unauthorized disclosure can be a breach even when no attacker penetrates the system. Diligence should establish the product's regulatory perimeter, map every health-data flow and authorization, test incident readiness, and model the capital and trust consequences of notification.[1]

Key takeaways

  • HIPAA is not the default shield for consumer health technology. A direct-to-consumer app outside HIPAA may still be a vendor of personal health records under the FTC rule.
  • Coverage can turn on technical capability. An app that accepts user health inputs and can draw other information through a wearable, API, geolocation service, or similar source may satisfy the multiple-source element.
  • Breach diligence must include product disclosures, pixels, software development kits, analytics, advertising, and vendor use - not only ransomware and stolen credentials.
  • Notice is an operational deadline. The company needs evidence-preserving investigation, decision authority, recipient identification, consumer communications, and regulatory coordination before an incident occurs.
  • Valuation should reflect remediation cost, customer and platform response, revenue interruption, consent redesign, deletion obligations, and governance capacity in addition to possible penalties.

Why this rule belongs in investment diligence

The FTC rule covers certain vendors of personal health records, PHR related entities, and third-party service providers that are not acting as HIPAA covered entities or solely as HIPAA business associates. It requires notice after a breach of unsecured PHR identifiable health information to affected people, the FTC, and in specified circumstances the media. The FTC's current compliance guide expressly contemplates fitness apps, connected devices, and hybrid companies that serve both consumers and HIPAA-regulated customers.[2]

That perimeter matters because a startup can look clinically credible while its privacy architecture remains consumer-grade. A physician advisor may focus on evidence quality, adherence, workflow, or safety while the commercial team adds analytics and acquisition tooling. Those additions can change which information leaves the product, who receives it, and whether consumer expectations align with actual processing. The resulting risk can emerge before any conventional security failure.

The rule is not a substitute for broader privacy analysis

The Health Breach Notification Rule answers a breach-notice question; it does not exhaust a company's obligations. The FTC Act prohibits unfair or deceptive practices, including misleading statements about health-data collection, use, retention, security, or sharing. HIPAA may govern separate enterprise data, and state consumer-health privacy and breach laws may add non-contradictory duties. HHS and the FTC recommend starting with the complete data flow, then testing safeguards, purposes, consent, retention, and consumer-facing representations.[4]

Determine whether the product is inside the FTC perimeter

Do not accept a slide that says HIPAA does not apply and end the analysis. Build a product-by-product, data-by-data classification. The amended rule defines a personal health record as an electronic record of identifiable health information on an individual that has the technical capacity to draw information from multiple sources and is managed, shared, and controlled by or primarily for the individual. The FTC's mobile health tool says most non-HIPAA health apps can be subject to the rule when this test is met.[3]

Four questions expose the coverage thesis

  • What record exists? Identify the electronic record the product offers or maintains, not merely the database name used by engineering.
  • Is the information identifiable and health-related? Include data that relates to health, care, payment, condition, treatment, medication, biometrics, fertility, location, or behavior when it can identify a person.
  • Can the record draw from multiple sources? Test current technical capacity, including user input plus devices, APIs, data brokers, geolocation, portals, or other integrations.
  • Who manages the record? Determine whether the record is managed, shared, and controlled by or primarily for the individual rather than only for a provider or plan.

The multiple-source test is easy to underestimate. The final rule explains that technical capacity can be enough even when an individual declines to connect the second source. Its example describes a depression-management app that accepts user input and can synchronize with a wearable sleep monitor; the record can qualify even if some users never enable the sync. The analysis is fact-intensive, but dormant assumptions are not a substitute for inspecting enabled product capability.[1]

Separate consumer, enterprise, and hybrid data paths

A startup may operate in more than one legal role. It might handle protected health information as a hospital's business associate while offering a separate subscription app directly to consumers. The FTC guide states that the FTC rule does not apply when a business acts solely as a HIPAA business associate, but the same company may face FTC and HHS notice duties when an incident reaches both populations.[2] Investors should require segregated inventories, contracts, access controls, incident playbooks, and responsibility maps for each path.

A breach can be a disclosure, not just an intrusion

The amended definition makes clear that a breach of security includes unauthorized acquisition resulting from a data breach or an unauthorized disclosure. The final rule discusses a medication app that sends identifiable health information to advertising or advertising-analytics companies contrary to its privacy representations or without affirmative express consent. It also explains that manipulative interfaces can undermine a claim that users made a meaningful choice.[1]

This shifts the investor's evidence request. A penetration test says little about whether an analytics software development kit receives medication events, an advertising pixel receives page context, or a customer-success tool retains free-text symptoms. The joint FTC-HHS warning to hospitals and telehealth providers specifically highlighted tracking technologies and told companies to monitor flows to third parties. It cited enforcement involving GoodRx and Premom as notice that unauthorized health-information disclosures can violate the FTC Act and may constitute a breach.[9]

Build a data-flow and authorization matrix

Diligence layer Evidence to inspect Investor interpretation
Collection Fields, event names, device permissions, APIs, inferred attributes, and production telemetry. Tests whether management's inventory matches what the product actually creates or receives.
Disclosure Recipient, payload, purpose, configuration, onward use, contract terms, and deletion controls. Reveals whether a vendor is merely processing data or can use it for its own advertising or product purposes.
Authorization Consent language, screen design, defaults, privacy statements, version history, and withdrawal path. Tests whether the company can prove meaningful, specific choice rather than relying on buried boilerplate.
Response Logs, owner, investigation protocol, notification templates, vendor escalation, and decision record. Shows whether the board can meet a time-bound obligation with defensible facts.

Reconcile the matrix against network traffic and vendor dashboards, not just contracts. Product teams often use one label such as analytics for services with different permissions and business models. Ask whether each recipient can combine data across customers, retain it after termination, build profiles, support advertising, or act on derived health inferences. Then compare those facts with what a reasonable user sees at the moment of collection or disclosure.

Use enforcement orders as control specifications

The GoodRx stipulated order is useful because it shows the operational reach of a resolution: future breach notices, limits on advertising disclosures, affirmative express consent, third-party deletion requests, a comprehensive privacy program, assessments, records, and compliance reporting.[7] The Premom matter alleged unauthorized sharing of sensitive health information with advertising and analytics recipients and failure to provide required breach notice; the settlement imposed limits, consent and deletion obligations, and programmatic controls.[8] These matters do not prove that every similar configuration violates the law, but they identify diligence areas with demonstrated enforcement relevance.

Notification mechanics create a compressed operating problem

For affected individuals, required notice must be sent without unreasonable delay and no later than 60 calendar days after discovery. For a breach involving 500 or more individuals, the FTC form instructs the company to notify the Commission at the same time it notifies affected people. For fewer than 500, FTC reporting is due by the sixtieth day of the calendar year following the breach. Different rules govern media notice, service-provider notice, law-enforcement delay, and the content and delivery of consumer notices.[5]

The sixty-day figure is an outer limit, not a default investigation period. The rule requires action without unreasonable delay. During that interval the company may need to preserve evidence, stop ongoing disclosures, determine the affected population, identify recipients, coordinate vendors and insurers, draft readable notices, evaluate state and contractual duties, answer customer questions, and support a board decision. An incomplete user identity model or unversioned privacy interface can make those tasks materially slower.

Test the incident playbook with a product-specific exercise

Give management a realistic scenario: a mobile analytics library received user identifiers plus symptom-screen results for six months, contrary to the startup's stated purpose. Ask who can disable the flow, whether prior payloads are reconstructable, how authorization is evaluated, how affected people are counted, who determines discovery, and who approves notice. Include the vendor, privacy lead, security lead, product owner, communications team, insurer, outside counsel, and board observer. A generic ransomware tabletop will not reveal product-disclosure gaps.

The FTC's business summary notes that failure to make required notices can lead to enforcement and significant civil penalties.[6] Avoid treating the current maximum penalty as a timeless valuation input because statutory penalty ceilings can be adjusted. The more durable underwriting focus is the number and duration of potential violations, consumer impact, remediation scope, injunction-like operating constraints, and management's ability to discover and correct the problem quickly.

The physician investor's seven-part diligence framework

1. Classify the business model and legal roles

Map every product, customer type, data source, and revenue stream. Identify where the company acts for consumers, providers, plans, employers, researchers, or advertisers. Record the evidence supporting each HIPAA, FTC-rule, service-provider, or other classification. Revisit the map when a new integration or channel launches; legal role can change with product facts.

2. Verify the production data map

Obtain the data inventory, architecture diagram, event taxonomy, vendor list, mobile permissions, API registry, and retention schedule. Sample actual production events through appropriate controlled methods. Include inferred conditions, device identifiers, IP addresses, geolocation, search terms, appointment activity, and page-level context. A map that excludes metadata may miss what makes health information identifiable.

3. Reconcile promises, consent, and practice

Version privacy policies, onboarding screens, settings, marketing claims, app-store disclosures, and enterprise representations. For every sensitive disclosure, identify the precise consumer-facing language and the record of choice. Test whether refusal is practical, whether purposes are specific, whether defaults and visual hierarchy are fair, and whether withdrawal propagates to downstream systems.

4. Audit vendors and software components

Rank vendors by access to identifiable health information and their ability to retain, combine, infer, or independently use it. Review configuration, not merely the master agreement. Require notification commitments, deletion support, audit evidence, subprocessor visibility, and restrictions aligned with product promises. Confirm that legacy pixels and inactive software kits have actually stopped transmitting.

5. Test detection and notification readiness

Inspect logging coverage, data-loss alerts, privacy review triggers, employee escalation, evidence preservation, incident classification, user enumeration, templates, regulator workflows, and board reporting. Review one prior incident or near miss from intake through closure. The company should be able to explain how it establishes when discovery occurred and why its notification timing is reasonable.

6. Price the downside in scenarios

Model at least three events: a contained vendor error, a smaller reportable disclosure, and a large multi-jurisdiction incident. Estimate investigation, forensics, engineering, vendor replacement, notice, call-center, credit or identity services if relevant, legal, insurance retention, customer concessions, platform response, deletion, consent redesign, and delayed roadmap cost. Keep possible enforcement and state-law exposure as ranges rather than false precision.

7. Match governance to the growth plan

Compare data sensitivity and integration velocity with privacy engineering, security, legal, product, and compliance capacity. Define board-level reporting for material data-flow changes, sensitive vendor additions, incidents, consumer complaints, and unresolved audit findings. Financing terms can require remediation milestones or reserves when privacy debt is measurable but not yet eliminated.

Valuation and deal terms: price trust as infrastructure

A compliant architecture can improve more than downside protection. Clear purpose limits, reliable consent records, disciplined vendor use, and fast incident response can shorten enterprise security review, support channel partnerships, reduce rework, and preserve physician and patient trust. Those capabilities deserve credit only when verified through systems and records; a privacy policy alone is not an asset.

When gaps are remediable, translate them into a dated operating plan. Examples include removing advertising-oriented software kits, implementing consent versioning, separating consumer and enterprise environments, validating deletion, renegotiating vendor rights, and exercising the notice playbook. Investment committees can use closing conditions, holdbacks, specific indemnities, insurance requirements, board information rights, or post-close milestones according to deal structure and advice from qualified counsel.

Red flags that should change valuation or timing

  • Management says the company is not subject to HIPAA and therefore has no federal health-privacy obligations.
  • The data inventory omits device identifiers, event properties, geolocation, inferences, test environments, or vendor-side retention.
  • A privacy policy promises no sale or sharing while advertising or analytics vendors can use data for their own purposes.
  • Consent is bundled, preselected, difficult to refuse, or unsupported by a versioned record tied to the disclosed data and recipient.
  • Security owns breach response, but nobody owns unauthorized product disclosures or consumer-notice decisions.
  • The company cannot recreate which users, payloads, recipients, configurations, and disclosures were active during a historical period.
  • Enterprise and direct-to-consumer data paths share tooling without a documented analysis of HIPAA, FTC, contract, and state-law roles.
  • The financial plan carries cyber insurance but no engineering, communication, customer-retention, or platform-remediation reserve.

A 100-day board plan after investment

In the first thirty days, authenticate the regulatory perimeter and freeze the current data-flow baseline. By day sixty, reconcile production telemetry, vendors, consent, privacy representations, and retention; eliminate any clearly unnecessary flow. By day one hundred, complete a product-disclosure tabletop, validate recipient deletion and shutdown procedures, approve a prioritized remediation budget, and establish quarterly board reporting. HHS maintains a current mobile-health resources page that connects developers to the joint federal interactive tool and related HIPAA, FTC, FDA, COPPA, and information-blocking guidance.[10]

Frequently asked questions

Does the FTC rule apply only after a cyberattack?

No. A breach can result from an intrusion, but it can also result from an unauthorized disclosure by the company, such as sending identifiable health information to an analytics or advertising recipient without valid authorization. The diligence question is therefore broader than whether the startup has been hacked.

Is a health app outside the rule if most users never connect a wearable?

Not necessarily. The amended definition focuses on whether the record has the technical capacity to draw information from multiple sources. An available synchronization or data-source capability can matter even if a particular user does not activate it. Coverage remains fact-specific.

Can a startup be subject to both FTC and HIPAA breach duties?

Yes. A company may act as a HIPAA business associate for an enterprise customer while separately offering a consumer product that is subject to the FTC rule. A single incident can require coordinated analysis under both regimes and under applicable state law.

What is the highest-value diligence artifact for investors?

Start with a current data-flow and authorization matrix that identifies every sensitive data element, source, recipient, purpose, legal or product basis, retention period, and deletion path. Reconcile it to production telemetry, contracts, privacy statements, consent screens, and vendor configurations.

How should investors model a possible health-data breach?

Use scenarios rather than one generic cybersecurity reserve. Separate a contained incident from a reportable event involving fewer than 500 people, a larger event requiring contemporaneous consumer and FTC notice, and a disclosure that also produces contract, state-law, platform, or enforcement consequences.

Conclusion

The FTC Health Breach Notification Rule turns health-app privacy from a policy-page exercise into an operational diligence problem. The decisive facts live in product capability, data flows, recipient rights, consumer authorization, and incident execution. Physician investors can add unusual value by connecting those facts to clinical sensitivity, user expectations, adoption, and trust. Underwrite the verified control environment, fund specific remediation, and preserve downside capacity for the disclosures the company has not yet learned to see.

References

  1. Federal Trade Commission. Health Breach Notification Rule, 16 CFR Part 318. Final Rule, May 30, 2024; effective July 29, 2024. Accessed August 2, 2026. https://www.federalregister.gov/documents/2024/05/30/2024-10855/health-breach-notification-rule
  2. Federal Trade Commission. Complying with FTC's Health Breach Notification Rule. Accessed August 2, 2026. https://www.ftc.gov/business-guidance/resources/complying-ftcs-health-breach-notification-rule-0
  3. Federal Trade Commission. Mobile Health App Interactive Tool. Accessed August 2, 2026. https://www.ftc.gov/business-guidance/resources/mobile-health-apps-interactive-tool
  4. U.S. Department of Health and Human Services and Federal Trade Commission. Collecting, Using, or Sharing Consumer Health Information? Look to HIPAA, the FTC Act, and the Health Breach Notification Rule. Accessed August 2, 2026. https://www.hhs.gov/hipaa/for-professionals/special-topics/hipaa-ftc-act/index.html
  5. Federal Trade Commission. Notice of Breach of Health Information reporting form and timelines. Accessed August 2, 2026. https://www.ftc.gov/business-guidance/health-breach-form
  6. Federal Trade Commission. Health Breach Notification Rule: The Basics for Business. Accessed August 2, 2026. https://www.ftc.gov/business-guidance/resources/health-breach-notification-rule-basics-business
  7. U.S. District Court for the Northern District of California. GoodRx Stipulated Order for Permanent Injunction, Civil Penalty Judgment, and Other Relief, February 2023. Accessed August 2, 2026. https://www.ftc.gov/system/files/ftc_gov/pdf/goodrx_stipulated_order_for_permanent_injunction_civil_penalty_judgment_and_other_relief.pdf
  8. Federal Trade Commission. Easy Healthcare Corporation, U.S. v. (Premom), case materials and settlement, June 2023. Accessed August 2, 2026. https://www.ftc.gov/legal-library/browse/cases-proceedings/202-3186-easy-healthcare-corporation-us-v
  9. Federal Trade Commission and HHS Office for Civil Rights. Warning to Hospital Systems and Telehealth Providers About Privacy and Security Risks from Online Tracking Technologies, July 2023. Accessed August 2, 2026. https://www.ftc.gov/news-events/news/press-releases/2023/07/ftc-hhs-warn-hospital-systems-telehealth-providers-about-privacy-security-risks-online-tracking
  10. U.S. Department of Health and Human Services, Office for Civil Rights. Resources for Mobile Health Apps Developers; reviewed April 22, 2026. Accessed August 2, 2026. https://www.hhs.gov/hipaa/for-professionals/special-topics/health-apps/index.html

Editorial disclaimer: This article is for educational purposes only and does not constitute medical, legal, tax, accounting, privacy, cybersecurity, regulatory, or investment advice. Requirements are fact-specific and can change. Readers should consult qualified professionals and verify current primary sources before acting.